“merck-kgaa” Archives

in
Entry Author Date Location
Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug 08/17/20 Europe
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer 06/19/19 San Diego
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer 04/22/19 New York
AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results 04/03/19 National
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More 02/08/19 National
Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More 08/24/18 National
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More 12/01/17 National
Chemo Tops Pfizer, Merck KGaA Drug in Big Stomach Cancer Test 11/28/17 New York
Mersana Plans IPO to Finance Clinical Trials for Breast Cancer Drug 06/02/17 Boston
Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More 01/13/17 National
Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug 11/02/16 Boston
Metis Foundation, Targeting Military Researchers, Plans Fund Raise 08/05/16 Texas
Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More 07/22/16 National
Syndax Cuts Price But Bags $53M in Second IPO Try 03/02/16 Boston
Déjà Vu For Gilman as New Immunology Startup, Padlock, Gets $23M 12/18/14 Boston
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
Celldex Touts Brain Cancer Vaccine Data, Talks FDA Strategy 11/14/14 New York
Madison Startup Rides Immunotherapy Wave With Prostate Drug 08/18/14 Wisconsin
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
East Coast Biotech Roundup: Vertex, Cubist, Editas, Polaris, & More 06/27/14 Boston
East Coast Biotech Roundup: Berg, Forma/Celgene, Intarcia, & More 04/04/14 Boston
Oncothyreon Stock Surges on Partner’s Renewed Bet in Lung Cancer 09/25/13 Seattle
Opexa Tries a Personalized Cell Therapy Against Last, Worst Stage of MS 05/02/13 Texas
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? 05/03/12 Seattle
Oncothyreon Shares Tumble on Lung Cancer Study Speculation 03/06/12 Seattle
Oncothyreon CEO Bob Kirkman Returns from Medical Leave 12/02/11 Seattle
Page 1 of 4 next page »